Skip to main content

Advertisement

Log in

Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy

Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

This study was conducted to evaluate the durability of clevudine-induced viral response after the withdrawal of treatment.

Methods

Patients who showed a complete response [alanine aminotransferase (ALT) normalization and hepatitis B virus (HBV) DNA <4,700 copies/mL for hepatitis B envelope antigen (HBeAg)-negative patients; ALT normalization, HBV DNA <4,700 copies/mL, and HBeAg seroconversion for HBeAg-positive patients] in the previous clevudine phase III trials were followed for an additional 96 weeks without any treatment for hepatitis B.

Results

Of the 63 patients in the study cohort, 73% and 35% of the patients had HBV DNA <141,500 and <4,700 copies/mL, respectively, and 75% of the patients had normal ALT at the end of follow-up. HBeAg seroconversion was maintained in 81% of the patients and hepatitis B surface antigen (HBsAg) loss occurred in 3 patients. Continued HBsAg titer decrease (−0.5 log IU/mL) was observed in the sustained viral responders, suggesting the reduction of covalently closed circular DNA in hepatocytes.

Conclusions

The clevudine-induced viral response was durable in the majority of patients for 2 years after the withdrawal of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Lee WM. Hepatitis B infection. N Engl J Med. 1997;337:1733–45.

    Article  PubMed  CAS  Google Scholar 

  2. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–17.

    Article  PubMed  CAS  Google Scholar 

  3. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527–32.

    Article  PubMed  CAS  Google Scholar 

  4. Perrilo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 2000;32:129–34.

    Article  Google Scholar 

  5. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129:1198–209.

    Article  PubMed  CAS  Google Scholar 

  6. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.

    Article  PubMed  CAS  Google Scholar 

  7. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–88.

    Article  PubMed  CAS  Google Scholar 

  8. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.

    Article  PubMed  CAS  Google Scholar 

  9. Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, et al. Use of 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother. 1995;39:979–81.

    PubMed  CAS  Google Scholar 

  10. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, et al. Antiviral activity of clevudine [l-FMAU, (1-(2-fluoro-5-methyl-beta, l-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology. 2001;33:254–66.

    Article  PubMed  CAS  Google Scholar 

  11. Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, et al. Preclinical investigation of l-FMAU as an anti-hepatitis B virus agent. Antivir Ther. 1998;3(suppl 3):113–21.

    PubMed  CAS  Google Scholar 

  12. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001;75:311–22.

    Article  PubMed  CAS  Google Scholar 

  13. Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA. 2004;101:638–40.

    Article  PubMed  CAS  Google Scholar 

  14. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007;45:1172–8.

    Article  PubMed  CAS  Google Scholar 

  15. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46:1041–8.

    Article  PubMed  CAS  Google Scholar 

  16. Chung YH, Lee KS, Kim JH, Ryu SH, Paik SW, Um SH, et al. One-year treatment with clevudine demonstrated significant viral suppression and biochemical improvement. J Hepatol. 2006;44:S25.

    Article  Google Scholar 

  17. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat. 2002;9:208–12.

    Article  PubMed  CAS  Google Scholar 

  18. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–6.

    Article  PubMed  CAS  Google Scholar 

  19. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462–8.

    Article  PubMed  CAS  Google Scholar 

  20. Menne S, Roneker CA, Tennant BC, Korba BE, Gerin JL, Cote PJ. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology. 2002;45:237–50.

    Article  PubMed  CAS  Google Scholar 

  21. Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009;51:829–34.

    Article  PubMed  Google Scholar 

  22. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009;49:2080–6.

    Article  PubMed  CAS  Google Scholar 

  23. Tak WY, Park SY, Cho CM, Jung MK, Jeon SW, Kweon YO, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol. 2010;53:261–6.

    Article  PubMed  CAS  Google Scholar 

  24. Kim JH, Yim HJ, Jung ES, Jung YK, Kim JH, Seo YS, et al. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. J Viral Hepat. 2010 [Epub ahead of print].

  25. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, et al. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat. 2010 [Epub ahead of print].

  26. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009;51:787–91.

    Article  PubMed  CAS  Google Scholar 

  27. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was sponsored by Bukwang Pharmaceutical Co. Ltd and in part by the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (Grant No. 02-PJ2-PG4-PT01-0034).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Byung Chul Yoo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, HS., Yoo, B.C., Lee, K.S. et al. Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy. J Gastroenterol 46, 410–414 (2011). https://doi.org/10.1007/s00535-010-0354-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-010-0354-x

Keywords

Navigation